EUVIMEDEUVIMED entdecken
Crossref

Statin labelling may overstate adverse events

Drug and Therapeutics Bulletin · 2026-05 · 64 (5) · 70-70

DOI: 10.1136/dtb.2026.000016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug and Therapeutics Bulletin, online erschienen am 29.04.2026. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Drug Labeling. Die Arbeit nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overview of: Cholesterol Treatment Trialists’ (CTT) Collaboration. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials. Lancet 2026;407(10529):689-703.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsDrug LabelingHumansRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Drug-Related Side Effects and Adverse ReactionsHealth Care Quality, Access, and Evaluation

Substanzen

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Zitieren

APA

(2026). Statin labelling may overstate adverse events. Drug and Therapeutics Bulletin, 64(5), 70-70. https://doi.org/10.1136/dtb.2026.000016

Vancouver

Statin labelling may overstate adverse events. Drug and Therapeutics Bulletin. 2026;64(5):70-70. doi:10.1136/dtb.2026.000016

BibTeX
@article{euvimed2026,
  title = {Statin labelling may overstate adverse events},
  journal = {Drug and Therapeutics Bulletin},
  year = {2026},
  volume = {64},
  number = {5},
  pages = {70--70},
  doi = {10.1136/dtb.2026.000016}
}
Kostenlos starten →